From a translational research perspective, our data draw striking parallels with recent clinical observations: patients with hematological malignancies receiving an allo-BMT from healthy donors with incidental DNMT3A mutations (most commonly loss-of-function and associated with asymptomatic CHIP) had higher rates of chronic GVHD, lower risk for relapse, and improved overall survival (14, 15). Here, DNMT3A is linked to hematologic disorder.